Determining genetic markers for platinumsensitivity in ovarian cancer
From 01-01-2010 to 01-01-2011
Description
Overall Aim of the proposal
In this proposal, we will use an unbiased approach to determine which genetic alterations (both mutations and copy numbers) and microRNAs are predictive for the incidence of ovarian cancer, subsequent disease prognosis, as well as efficacy of chemotherapy. By dividing our study population in platinum-responsive and platinum-resistant phenotypes, we will especially focus on determining genetic markers for platinum-sensitivity. Understanding the genetic basis underlying platinum resistance will lead to more effective individualized treatments and will avoid exposing patients unnecessarily to damaging, ineffective and costly agents. This would increase the quality of life and hopefully the survival of the patient and in addition, a reduction in the treatment expenses is expected.
Team
- Bart De Moor, Co-promoter
Financing
Funding: OTHER - Other Funding Agencies
Program/Grant Type: LKI - Leuven Kanker Instituut
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.
